Axel Heidenreich, Dirk Böhmer, Christian Bolenz, Angelika Borkowetz, Constantin Rieger, Maria De Santis
{"title":"膀胱尿路上皮癌的新膀胱保存策略。","authors":"Axel Heidenreich, Dirk Böhmer, Christian Bolenz, Angelika Borkowetz, Constantin Rieger, Maria De Santis","doi":"10.3238/arztebl.m2025.0014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>17 500 persons receive a new diagnosis of urothelial carcinoma of the bladder in Germany each year. Radical cystectomy is performed for muscle-invasive and for non-muscle-invasive, recurrent, high-risk tumors. Because this procedure carries a perioperative complication rate of 30-40% and impairs the patients' quality of life, options have been developed for intravesical and systemic bladder-preserving treatment.</p><p><strong>Methods: </strong>This review is based on pertinent publications (up to July 2024) on bladder-preserving treatment methods that were retrieved by a selective search in the PubMed, Web of Science, and Cochrane Library databases.</p><p><strong>Results: </strong>Multiple clinical phase II-III trials and observational studies are available. Carefully selected patients with recurrent, non-muscle-invasive, high-risk urothelial carcinoma received bladder-preserving treatment of the following kinds: intravesical chemotherapy with or without hyperthermia (52-65% progressionfree at 2-3 years); drug-coated carrier systems (complete remission, 50-83%); viral gene therapy (complete remission, 53%); systemic immunotherapy with checkpoint inhibitors (19-44% recurrence-free at 1 year). The rate of bladder preservation was 49-100%. No worsening of overall survival was observed. Treatments for muscle-invasive urothelial carcinoma included neoadjuvant chemotherapy followed by frequent follow-up, radical transurethral tumor resection, partial cystectomy, and trimodal radiochemotherapy (TMRT). Only TMRT yielded comparable long-term oncological results to those of cystectomy, with a 74% rate of freedom from metastases and an overall survival rate of 73%. Any type of bladder-preserving treatment requires meticulous long-term urooncological follow-up, with repeated cystoscopies, bladder biopsies, urine cytologies, and multiparametric bladder MRI.</p><p><strong>Conclusion: </strong>Bladder-preserving treatments should be considered part of the therapeutic armamentarium and should be critically discussed in an interdisciplinary setting.</p>","PeriodicalId":11258,"journal":{"name":"Deutsches Arzteblatt international","volume":" Forthcoming","pages":"211-218"},"PeriodicalIF":6.5000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Bladder Preservation Strategies in Urothelial Carcinoma of the Bladder.\",\"authors\":\"Axel Heidenreich, Dirk Böhmer, Christian Bolenz, Angelika Borkowetz, Constantin Rieger, Maria De Santis\",\"doi\":\"10.3238/arztebl.m2025.0014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>17 500 persons receive a new diagnosis of urothelial carcinoma of the bladder in Germany each year. Radical cystectomy is performed for muscle-invasive and for non-muscle-invasive, recurrent, high-risk tumors. Because this procedure carries a perioperative complication rate of 30-40% and impairs the patients' quality of life, options have been developed for intravesical and systemic bladder-preserving treatment.</p><p><strong>Methods: </strong>This review is based on pertinent publications (up to July 2024) on bladder-preserving treatment methods that were retrieved by a selective search in the PubMed, Web of Science, and Cochrane Library databases.</p><p><strong>Results: </strong>Multiple clinical phase II-III trials and observational studies are available. Carefully selected patients with recurrent, non-muscle-invasive, high-risk urothelial carcinoma received bladder-preserving treatment of the following kinds: intravesical chemotherapy with or without hyperthermia (52-65% progressionfree at 2-3 years); drug-coated carrier systems (complete remission, 50-83%); viral gene therapy (complete remission, 53%); systemic immunotherapy with checkpoint inhibitors (19-44% recurrence-free at 1 year). The rate of bladder preservation was 49-100%. No worsening of overall survival was observed. Treatments for muscle-invasive urothelial carcinoma included neoadjuvant chemotherapy followed by frequent follow-up, radical transurethral tumor resection, partial cystectomy, and trimodal radiochemotherapy (TMRT). Only TMRT yielded comparable long-term oncological results to those of cystectomy, with a 74% rate of freedom from metastases and an overall survival rate of 73%. Any type of bladder-preserving treatment requires meticulous long-term urooncological follow-up, with repeated cystoscopies, bladder biopsies, urine cytologies, and multiparametric bladder MRI.</p><p><strong>Conclusion: </strong>Bladder-preserving treatments should be considered part of the therapeutic armamentarium and should be critically discussed in an interdisciplinary setting.</p>\",\"PeriodicalId\":11258,\"journal\":{\"name\":\"Deutsches Arzteblatt international\",\"volume\":\" Forthcoming\",\"pages\":\"211-218\"},\"PeriodicalIF\":6.5000,\"publicationDate\":\"2025-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Deutsches Arzteblatt international\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3238/arztebl.m2025.0014\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsches Arzteblatt international","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3238/arztebl.m2025.0014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:在德国,每年有17500人被诊断为膀胱尿路上皮癌。根治性膀胱切除术适用于肌肉侵袭性和非肌肉侵袭性、复发性、高风险肿瘤。由于该手术的围手术期并发症发生率为30-40%,并损害患者的生活质量,因此已经开发出膀胱内和全身膀胱保留治疗的选择。方法:本综述基于PubMed、Web of Science和Cochrane Library数据库中选择性检索的有关膀胱保留治疗方法的相关出版物(截至2024年7月)。结果:有多个临床II-III期试验和观察性研究。精心挑选的复发性、非肌肉侵袭性、高风险尿路上皮癌患者接受以下类型的保膀胱治疗:膀胱内化疗伴或不伴热疗(2-3年无进展52-65%);药物包被载体系统(完全缓解,50-83%);病毒基因治疗(完全缓解,53%);使用检查点抑制剂进行全身免疫治疗(1年无复发率19-44%)。膀胱保存率为49% ~ 100%。未观察到总生存期恶化。肌肉侵袭性尿路上皮癌的治疗包括新辅助化疗、频繁随访、经尿道肿瘤根治性切除术、部分膀胱切除术和三模式放化疗(TMRT)。只有TMRT产生了与膀胱切除术相当的长期肿瘤结果,转移自由率为74%,总生存率为73%。任何类型的保膀胱治疗都需要细致的长期泌尿肿瘤随访,包括反复的膀胱镜检查、膀胱活检、尿细胞学检查和多参数膀胱MRI。结论:膀胱保留治疗应被视为治疗手段的一部分,并应在跨学科环境中进行批判性讨论。
New Bladder Preservation Strategies in Urothelial Carcinoma of the Bladder.
Background: 17 500 persons receive a new diagnosis of urothelial carcinoma of the bladder in Germany each year. Radical cystectomy is performed for muscle-invasive and for non-muscle-invasive, recurrent, high-risk tumors. Because this procedure carries a perioperative complication rate of 30-40% and impairs the patients' quality of life, options have been developed for intravesical and systemic bladder-preserving treatment.
Methods: This review is based on pertinent publications (up to July 2024) on bladder-preserving treatment methods that were retrieved by a selective search in the PubMed, Web of Science, and Cochrane Library databases.
Results: Multiple clinical phase II-III trials and observational studies are available. Carefully selected patients with recurrent, non-muscle-invasive, high-risk urothelial carcinoma received bladder-preserving treatment of the following kinds: intravesical chemotherapy with or without hyperthermia (52-65% progressionfree at 2-3 years); drug-coated carrier systems (complete remission, 50-83%); viral gene therapy (complete remission, 53%); systemic immunotherapy with checkpoint inhibitors (19-44% recurrence-free at 1 year). The rate of bladder preservation was 49-100%. No worsening of overall survival was observed. Treatments for muscle-invasive urothelial carcinoma included neoadjuvant chemotherapy followed by frequent follow-up, radical transurethral tumor resection, partial cystectomy, and trimodal radiochemotherapy (TMRT). Only TMRT yielded comparable long-term oncological results to those of cystectomy, with a 74% rate of freedom from metastases and an overall survival rate of 73%. Any type of bladder-preserving treatment requires meticulous long-term urooncological follow-up, with repeated cystoscopies, bladder biopsies, urine cytologies, and multiparametric bladder MRI.
Conclusion: Bladder-preserving treatments should be considered part of the therapeutic armamentarium and should be critically discussed in an interdisciplinary setting.
期刊介绍:
Deutsches Ärzteblatt International is a bilingual (German and English) weekly online journal that focuses on clinical medicine and public health. It serves as the official publication for both the German Medical Association and the National Association of Statutory Health Insurance Physicians. The journal is dedicated to publishing independent, peer-reviewed articles that cover a wide range of clinical medicine disciplines. It also features editorials and a dedicated section for scientific discussion, known as correspondence.
The journal aims to provide valuable medical information to its international readership and offers insights into the German medical landscape. Since its launch in January 2008, Deutsches Ärzteblatt International has been recognized and included in several prestigious databases, which helps to ensure its content is accessible and credible to the global medical community. These databases include:
Carelit
CINAHL (Cumulative Index to Nursing and Allied Health Literature)
Compendex
DOAJ (Directory of Open Access Journals)
EMBASE (Excerpta Medica database)
EMNursing
GEOBASE (Geoscience & Environmental Data)
HINARI (Health InterNetwork Access to Research Initiative)
Index Copernicus
Medline (MEDLARS Online)
Medpilot
PsycINFO (Psychological Information Database)
Science Citation Index Expanded
Scopus
By being indexed in these databases, Deutsches Ärzteblatt International's articles are made available to researchers, clinicians, and healthcare professionals worldwide, contributing to the global exchange of medical knowledge and research.